| Bioactivity | ADT-007 is a potent and orally active pan-RAS inhibitor with strong anticancer effects. ADT-007 binds RAS in a nucleotide-free conformation to block GTP activation. ADT-007 potently and selectively inhibits the growth of cancer cells with mutated or hyper-activated wild-type RAS isozymes[1]. |
| Invitro | ADT-007 显示出抑制 KRASG13D HCT-116 细胞生长的最高效力和选择性，IC50 为 5 nM，而 RAS 110 野生型 HT-29 细胞的敏感性要低约 100 倍，IC50 为 493 nM。ADT-007 在 KRAS G12C MIA PaCa-2 PDA 细胞中显示出更强的效力，导致 IC50 值低至 2 nM。ADT-007 还可有效抑制其他三种具有 G12V 或 G12D 突变的 KRAS PDA 突变细胞系的生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> ADT-007 相关抗体: |
| In Vivo | ADT-007（10 mg/kg；肿瘤内注射；每天一次；持续 17-21 天）强烈抑制同基因免疫活性小鼠结直肠癌模型中的肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1945941-09-2 |
| Formula | C26H24FNO5 |
| Molar Mass | 449.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jeremy B Foote, et al. A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer. bioRxiv[Preprint]. 2024 Jan 24:2023.05.17.541233. |